Arvinas, Inc.

ARVN Healthcare Biotechnology

Arvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 1,014.7%, EPS grew 410.7%, free cash flow grew 49.8% and total debt fell 40.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

7.14 0.31 −4.16%
Market cap
$487.1M
P/E
57.3×
Fwd P/E
−2.7×
Dividend yield
—
F-score
5/9
Altman Z
−0.61
Beneish M
−1.60
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
63.92 0.00 0.00 0.00

+8 more quarters

P/S ratio
1.70 7.59 3.20 2.00
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(11.15) (9.80) (27.66) (10.55)
P/B ratio
0.96 1.75 1.94 1.11
Price to Tangible BV
0.96 1.75 1.94 1.11
EV/Sales
(0.09) 0.73 0.60 (0.52)
EV/EBITDA
1.56 0.00 0.00 1.53
EV/Operating CF
0.13 (0.26) (0.57) 0.50
EV/FCF
0.13 (0.25) (0.57) 0.49
Quick Ratio
7.54 5.36 4.85 5.62
Current Ratio
7.91 5.44 4.92 5.70
Net Debt/EBITDA
(3.40) 9.59 9.06 17.42
Debt/Assets
0.04% 0.05% 0.06% 0.05%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.40 0.11 0.29 0.31
Operating CF/Net income
(0.29) 1.20 0.45 1.68
Capex/Depreciation
(0.07) 4.33 0.20 0.07
Research and Development Expense of Revenue
21.07% 386.54% 643.16% 154.42%
Selling, General and Administrative Expense of Revenue
9.61% 122.44% 242.11% 50.12%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
2.36% 77.56% 89.47% 24.34%
Graham Net Nets
1.00 0.55 0.50 0.88
Graham Number
5.04 0.00 0.00 0.00
Earnings Yield
1.56% (31.32%) (10.79%) (9.51%)
Free Cash Flow Yield
(38.78%) (37.87%) (32.79%) (52.83%)
Revenue per Share
3.85 0.24 0.13 0.57
Operating CF per Share
(0.75) (1.08) (0.43) (0.81)
Capex per Share
0.00 (0.02) 0.00 0.00
Free Cash Flow per Share
(0.75) (1.10) (0.43) (0.81)
Cash per Share
8.76 9.61 9.67 10.76
Shareholders Equity per Share
8.68 6.04 6.12 7.71
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
8.68 6.04 6.12 7.71
Free Cash Flow
(48.50) (70.50) (30.60) (59.20)
Working Capital
569.70 514.80 558.20 681.40
Capital Expenditures
(0.20) (1.30) (0.20) (0.10)
Net Current Asset Value
539.30 370.00 416.70 546.40
EV/EBIT
1.54 0.00 0.00 1.59
Capex to Sales
0.00 0.08 0.02 0.00
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Receivables
32.70 7.40 10.05 20.80
Average Payables
52.65 66.70 70.65 65.70
Average Assets
792.20 824.30 904.65 1,005.70
Average Common Equity
585.75 523.45 497.80 575.20

Fold the line items

Columns are period end dates